Australia's biggest pharmacy chain just set its sights on one of Britain's most iconic retail brands.
Sigma Healthcare, the ASX-listed parent of Chemist Warehouse, this week confirmed it is in preliminary talks with US private equity firm Sycamore Partners over a potential acquisition of Boots, the UK's dominant pharmacy chain with roughly 1,800 stores and a 40% market share. The deal is being talked at anywhere between $10 and $14 billion, which would make it the biggest offshore acquisition by an Australian company since CSL bought Swiss drugmaker Vifor for $18.8 billion in 2022.
Sigma is not the only bidder. Canada's Weston family, which controls Loblaws and Shoppers Drug Mart, is also in the running, and a successful Sigma bid would kill off Boots' planned London IPO. Goldman Sachs is advising Sigma on the process.
The strategic logic is straightforward. Sigma has been building a UK presence quietly, buying a 75% stake in Greenlight Healthcare in May to pilot the Chemist Warehouse brand across 22 London pharmacies. Boots would be a quantum leap, giving Sigma instant scale, a trusted brand, and a platform across 11 countries. Chemist Warehouse co-founder Mario Verrocchi has been blunt about his view of Boots: "Boots used to be my hero. Today, I would say no way in hell. Boots have lost their way." That's not the language of someone buying a trophy asset. It's the language of someone who thinks they can fix it.
The risk is real too. Sigma has a $33 billion market cap and would need to raise significant capital to fund a deal of this size. The company has repeatedly cited Bunnings' failed UK expansion as a cautionary tale about moving too fast offshore. For a management team that built its reputation on discipline, a $14 billion bet on a struggling British retailer is a big ask.
